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Duncan MacCannell, Andre Charlett, Matthias Egger, Jonathan Green, Paolo Vineis, Ibrahim Abubakar
Molecular data are now widely used in epidemiological studies to investigate the transmission, distribution, biology, 
and diversity of pathogens. Our objective was to establish recommendations to support good scientifi c reporting of 
molecular epidemiological studies to encourage authors to consider specifi c threats to valid inference. The statement 
Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID) builds upon the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) initiative. The STROME-ID 
statement was developed by a working group of epidemiologists, statisticians, bioinformaticians, virologists, and 
microbiologists with expertise in control of infection and communicable diseases. The statement focuses on issues 
relating to the reporting of epidemiological studies of infectious diseases using molecular data that were not 
addressed by STROBE. STROME-ID addresses terminology, measures of genetic diversity within pathogen 
populations, laboratory methods, sample collection, use of molecular markers, molecular clocks, timeframe, 
multiple-strain infections, non-independence of infectious-disease data, missing data, ascertainment bias, 
consistency between molecular and epidemiological data, and ethical considerations with respect to infectious-
disease research. In total, 20 items were added to the 22 item STROBE checklist. When used, the STROME-ID 
recommendations should advance the quality and transparency of scientifi c reporting, with clear benefi ts for 
evidence reviews and health-policy decision making.
Background
Through the synthesis of epidemiology and molecular 
biology, a powerful set of scientifi c methods have been 
developed to investigate the transmission, distribution, 
biology, and diversity of infectious organisms.1 The term 
molecular epidemiology emerged to describe this fi eld 
in 1973, in relation to infl uenza virus strains.2 Many 
technological advances have been made since that time, 
with typing methods undergoing a process of near-
continuous evolution. Molecular epidemiology has been 
variously defi ned3–6 and applied to many non-infectious 
settings.7–9 To set the focus for this statement and to be 
inclusive of past, present, and future technologies, we 
have selected the following defi nition for infectious-
disease molecular epidemiology:10 the use of molecular-
typing methods for infectious agents in the study of the 
distribution, dynamics, and determinants of health and 
disease in human populations.
Pathogen typing was once mainly phenotypic,1,11 but 
this approach has been largely superseded by four broad 
types of genetic analysis:11–13 direct comparison of DNA 
or RNA sequence data (including whole-genome 
sequencing); use of gel electrophoresis to compare band 
patterns, which can derive from pathogen-specifi c PCR 
amplifi cation products or DNA fragmentation by 
restriction endonuclease enzymes that cut DNA at 
specifi c recognition sequences; use of fl uorescently 
labelled nucleotides to measure the accumulation of 
PCR products; and use of hybridisation, in which short 
nucleic-acid recognition sequences (probes) are attached 
to a matrix to compare gene expression or diff erent 
genotypes of pathogens.
The basic assumption underlying most molecular 
epidemiological studies is that pathogens with similar 
profi les (as measured by molecular typing) are probably 
related, and that the degree of similarity between strains 
can be used to infer the time since their divergence.10 
Molecular-typing data (informed by appropriate 
epidemiological data relating to infected hosts or a point 
source) can thus be used to test epidemiological 
hypotheses as to whether cases are linked by recent 
transmission events or not.11 Epidemiological studies 
increasingly use such data, for example from routine 
surveillance or out break investigations, to increase the 
precision of case defi nitions and explore the determinants 
of disease transmission.
Applications of molecular epidemiology include 
measurement of the geographical distribution of 
pathogen strains over time, place, and person to inform 
outbreak investigations and assess prevention and 
control interventions; contribution to surveillance 
programmes (eg, to identify the emergence of clinically 
important phenotypes); support for investigations into 
transmission dynamics and clustering of infections; 
understanding the evolution of pathogens; to inform 
the classifi cation and identifi cation of new species; 
vaccine design and monitoring for escape mutants; and 
understanding why infections recur. Recent specifi c 
examples with direct applicability to public health 
include the use of whole-genome sequencing to verify 
an outbreak of meticillin-resistant Staphylococcus aureus 
in a special-care baby unit and to trace the source to a 
health-care worker carrier;14,15 characterisation and 
linking of cases of infection with the Shiga-toxin-
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producing Escherichia coli 0104:H4 strain by real-time 
whole-genome sequencing during an outbreak in 
Germany in 2011;16,17 and the fi nding of rapid global 
transmission of infl uenza A H1N1 during the 2009 
pandemic.13,18
In some studies, functional genomic diff erences 
within a pathogen species are of interest in their own 
right. These studies use epidemiological observational 
designs to assess associations between functional 
characteristics (eg, pathogenesis, clinical symptoms, and 
drug resistance) and genetic characteristics. Technology 
for whole-genome sequencing will lead to these studies 
becoming increasingly common in the future.
The number of published articles about molecular 
epidemiology in infectious disease has increased 
rapidly (fi gure). In a search of PubMed with the terms 
“infection” AND “molecular epidemiology”, we ident-
ifi ed more than 10 000 articles published between 1975 
and 2010, with more than 1000 added in 2010. However, 
scientifi c publications are of varying quality,19 have not 
consistently included true epidemiological applications 
(the term molecular epidemiology is sometimes used to 
describe studies that were never intended to be 
epidemiological).20 Epidemiological studies are subject 
to several threats to valid inference (eg, selection bias, 
uncontrolled confounding, and failure to identify and 
report stratifi ed results in the presence of eff ect 
modifi cation),20 and reporting practices can be poor.21–23
In other epidemiological subspecialties, prominent 
statements setting out detailed recommendations aim to 
provide guidance to authors and journals for the 
reporting of research. These statements include the 
Consolidating Standards of Reporting Trials (CONSORT) 
statement,24 the Outbreak Reports and Intervention 
Studies of Nosocomial Infection (ORION) statement,25 
the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) initiative,21,26 the 
Strengthening the Reporting of Genetic Association 
Studies (STREGA) statement,27,28 and the Reporting of 
Tumour Marker Studies (REMARK) statement.29 When 
adopted, such statements improve the quality of 
reporting in research, inform the use of appropriate 
terminology, and set minimum standards for com-
parison, with clear benefi ts for meta-analyses, evidence 
reviews, and decision making in public health. A recent 
STROBE extension, STROBE for Molecular Epi-
demiology (STROBE-ME), addressed reporting issues 
associated with the use of human biomarkers in 
epidemiological studies but did not deal with issues 
specifi c to infectious diseases.30 So far, no statements 
(with the exception of ORION) have mentioned 
infectious diseases. Although other authors have 
identifi ed reporting issues that arise in bacterial 
molecular epidemiology,31 no comprehensive statement 
that systematically addresses the full range of issues 
relating to the reporting of the design, collection, 
collation, and analysis of molecular epidemiological data 
for infectious diseases has been published.
Aims and use of the STROME-ID statement
We aim to extend the STROBE statement, with reference 
to other statements when appropriate, to improve and 
standardise the reporting of infectious-disease molecular 
data in epidemiological research. Our intention is to 
explain how to report research comprehensively, not to 
dictate how research should be done. The new statement 
extension, Strengthening the Reporting of Molecular 
Epidemiology for Infectious Diseases (STROME-ID), 
provides a checklist of items that should be read in 
conjunction with the STROBE statement (table). We 
specifi cally excluded guidance for studies about the 
genetics of human hosts and human biomarkers, for 
which detailed guidance is provided by STREGA and 
STROBE-ME, respectively.27,28,30 The STROME-ID 
statement there fore focuses on aspects of reporting for 
which epi demi ological studies that include infectious-
disease molecular data diff er from epidemiological 
studies without such data. We give detailed descriptions 
and provide background information in the appendix. 
The explicit aim of this statement is to improve the 
reporting of studies and, in turn, to assist interpretation 
of the data and in crease understanding of what was 
actually done by researchers.
Figure: Number of papers per 100 000 published per year identifi ed with the search terms “infection” AND 
“molecular epidemiology” in the Medline database in that year
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Development of standards
The STROME-ID statement was developed by a core 
working group, which met and communicated to agree 
the structure and content of the statement. Consensus 
was sought and reached by circulating iterative versions 
and teleconferences to discuss and to agree content. We 
intentionally sought a broad authorship group to include 
several institutions, countries, and specialties. We incl-
uded epidemiologists, statisticians, bioinformaticians, 
virologists, and microbiologists who were specialists in 
infectious diseases, molecular epidemiology, public 
health, and control of communicable diseases.
Overall, the structure of the STROME-ID statement 
follows the model of STROBE and other similar 
statements. Specifi cally, STROME-ID has been developed 
as an extension to the STROBE statement and the points 
should be read in addition to the 22 elements of STROBE 
(table).
STROME-ID standards
Title and abstract
Introduction
The term molecular epidemiology should be applied to 
the study in the title or abstract and the keywords when 
molecular and epidemiological methods contribute 
substantially to the study (STROME-ID 1.1). Appropriate 
use of terminology is essential to enable identifi cation of 
relevant research information. Studies can be tagged 
with inaccurate medical subject heading (MeSH) labels, 
which reduces their usefulness as search terms.32,33 The 
term molecular epidemiology should therefore be used 
to describe infectious-disease research with true 
molecular and analytical epidemiological components.20 
Authors reporting fi ndings from studies of pathogen 
typing without epidemiological analyses should avoid 
use of the term.
Background rationale
Provide background information about the pathogen 
population and the distribution of pathogen strains 
within the host population at risk (STROME-ID 2.1). 
Phylogeographical diff erences between regions and 
populations in the distribution of strains can be 
substantial. For this reason, the distribution of pathogen 
strains within the host population should be stated, 
when available, to provide context for the study and to 
assist interpretation of fi ndings. The level of detail 
should be appropriate to the study setting and the 
research question. An evolving example is that of 
measles.34 Measles genotyping for surveillance uses a 
small sequencing window of the measles N gene (N-
450).35 However, because transmission chains are 
increasingly interrupted by vaccination the genetic 
variability of strains in some areas has decreased, which 
limits the discriminatory ability of genotyping the N-450 
sequence.34 As such, the variability within the population 
under study is needed to enable assessment of whether 
the sequencing window is suffi  ciently wide to maintain 
sensitivity in areas approaching measles elimination.34
Objectives
State the epidemiological objectives of using molecular 
typing (STROME-ID 3.1). The study introduction should 
provide a clear rationale for the methods used and inform 
the reader of the epidemiological objectives of molecular 
typing in the context of the study design. In doing so, 
citation of any previous methodological studies that 
justify the use of the molecular techniques for the aims 
described and stating of their performance characteristics 
(eg, discriminatory power and marker stability) is helpful 
(appendix).
Methods
Study design
Defi ne or cite defi nitions for key molecular terms used 
within the study (eg, strain, isolate, and clone; 
STROME-ID 4.1). The precise meaning of some terms—
such as strain, isolate, clone, and clade—depends on the 
study question, the molecular techniques used, and the 
pathogen.36 As for many aspects of the STROME-ID 
statement, defi nitions are important for reasons of 
consistency and comparability, and we recommend, as 
an overriding general principle, that authors provide or 
cite the intended defi nitions of key terms.
We do not provide a full glossary of terms here because 
these are often context dependent. An exception is the 
term strain, which is widely used in this statement and is 
essential to most molecular epidemiological studies, 
partly because strains can have very diff erent functional 
characteristics.37–39 Most molecular methods defi ne 
strains using a small number of markers, which by 
defi nition can fail to take into account potential 
diff erences in other parts of the pathogen genome. With 
the exception of whole-genome sequencing, strain 
identity is therefore inferred rather than proven in many 
cases. We suggest the following, intentionally broad, 
defi nition as a guide: a group of pathogens that share an 
indistinguishable genome sequence by descent,36 but 
which, by the molecular technique or techniques used, 
are measurably distinct from other pathogens of the 
same species.10 However, we recognise that this defi nition 
might not be appropriate to all studies or pathogens, and 
that a more functional defi nition (provided or referenced 
by authors) might be needed for some publications.
Clearly defi ne the molecular markers that were used 
with a standard nomenclature (STROME-ID 4.2). A 
molecular marker is a phenotypic, proteomic, or genetic 
characteristic (in this case of a pathogen) that can be used 
to diff erentiate between isolates within a species. The 
level of resolution of the molecular markers used in the 
study should be suffi  cient to satisfy the molecular 
epidemiological objectives (appendix).
Clearly state the infectious-disease case defi nitions 
(STROME-ID 4.3). The infectious-disease case defi nition 
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Item 
number
STROBE items STROME-ID items
Title and abstract
Introduction 1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found
STROME-ID 1.1: the term molecular epidemiology should be applied to the study in 
the title or abstract and the keywords when molecular and epidemiological methods 
contribute substantially to the study
Background 
rationale
2 Explain the scientifi c background and rationale for the investigation 
being reported
STROME-ID 2.1: provide background information about the pathogen population 
and the distribution of pathogen strains within the host population at risk
Objectives 3 State specifi c objectives, including any prespecifi ed hypotheses STROME-ID 3.1: state the epidemiological objectives of using molecular typing
Methods
Study design 4 Present key elements of study design early in the paper ··
Molecular 
terminology
·· STROME-ID 4.1: defi ne or cite defi nitions for key molecular terms used within the 
study (eg, strain, isolate, and clone)
Molecular markers ·· STROME-ID 4.2: clearly defi ne the molecular markers that were used with a standard 
nomenclature
Infectious disease 
case defi nition
·· STROME-ID 4.3: clearly state the infectious-disease case defi nitions
Laboratory 
methodology
·· STROME-ID 4.4: describe sample collection and laboratory methods, including any 
methods used to minimise and measure cross-contamination, and give the criteria used 
to interpret strain classifi cation
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection
STROME-ID 5.1: clearly state the timeframe of the study; consider and appropriately 
reference the molecular clock of markers if known, and the natural history of the 
infection
Participants 6 (a) Cohort study—give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods of follow-up
Case-control study—give the eligibility criteria, and the sources and 
methods of case ascertainment and control selection. Give the rationale 
for the choice of cases and controls
Cross-sectional study—give the eligibility criteria, and the sources and 
methods of selection of participants
(b) Cohort study—for matched studies, give matching criteria and 
number of exposed and unexposed
Case-control study—for matched studies, give matching criteria and the 
number of controls per case
STROME-ID 6.1: state the source of participants and clinical specimens, and clearly 
describe sampling frame and strategy
Variables 7 Clearly defi ne all outcomes, exposures, predictors, potential confounders, 
and eff ect modifi ers. Give diagnostic criteria, if applicable
··
Data sources/
measurement
8* For each variable of interest give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group
··
Multiple-strain 
infections
·· STROME-ID 8.1: describe any methods used to detect multiple-strain infections and 
measure their eff ect on the study fi ndings
Bias 9 Describe any eff orts to address potential sources of bias STROME-ID 9.1: describe any eff orts made to address discovery or ascertainment bias
Study size 10 Explain how the study size was arrived at STROME-ID 10.1: describe any unique restrictions placed on the study sample size
Quantitative 
variables
11 Explain how quantitative variables were handled in the analyses. 
If applicable, describe which groupings were chosen, and why
··
Statistical 
methods
12 (a) Describe all statistical methods, including those used to control for 
confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—if applicable, explain how loss to follow-up was addressed
Case-control study—if applicable, explain how matching of cases and 
controls was addressed
Cross-sectional study—if applicable, describe analytical methods taking 
account of sampling strategy
(e) Describe any sensitivity analyses
STROME-ID 12.1: state how the study took account of the non-independence of sample 
data, if appropriate
STROME-ID 12.2: state how the study dealt with missing data
Results
Participants 13* (a) Report the numbers of individuals at each stage of the study (eg, 
numbers potentially eligible, examined for eligibility, confi rmed eligible, 
included in the study, completing follow-up, and analysed)
(b) Give reasons for non-participation at each stage
(c) Consider use of a fl ow diagram
STROME-ID 13.1: Report numbers of participants and samples at each stage of the 
study, including the number of samples obtained, the number typed, and the 
number yielding data
STROME-ID 13.2: if the study investigates groups of genetically indistinguishable 
pathogens (molecular clusters), state the sampling fraction, the distribution of 
cluster sizes, and the study population turnover, if known
(Table continues on next page)
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should be stated with a level of detail appropriate to the 
study question. The case defi nition can include 
symptoms, anatomical site of sample collection, typing 
information, methods to distinguish between carriers 
and cases (eg, to distinguish between contacts who are 
asymptomatically colonised with Neisseria meningitidis 
and cases of invasive disease40), identifi cation of chronic 
or recent infections (eg, strict serological defi nitions are 
needed to distinguish between acute and chronic 
infections with viral hepatitis41,42), and relevant exclusions 
(eg, smear-negative or extrapulmonary Mycobacterium 
tuberculosis).43 When the study objective is to investigate 
transmission within a population, care should be taken 
that several isolates from an individual patient do not 
bias measures of relatedness in a sample.
Inclusion of molecular-typing characteristics within the 
case defi nition can increase the precision of the defi 
nition 
and reduce the likelihood of misclassifi cation. Improved 
precision will tend to reduce the number of cases needed 
to establish an association and improve accuracy of 
statistical estimations in molecular epidemiological 
studies. When molecular characteristics are included 
within the case defi nition, particular care should be taken 
to ensure that comparable defi nitions have been used.44
Describe sample collection and laboratory methods, 
including any methods used to minimise and measure 
cross-contamination, and give the criteria used to 
interpret strain classifi cation (STROME-ID 4.4). Authors 
should include detailed microbiological and practical 
methodological descriptions of sample collection and 
processing, both to inform the reader if they might aff ect 
interpretation, and to ensure reproducibility of the study. 
Setting (eg, community vs health-care, how the samples 
were collected, or the laboratories used), sample type, 
Item 
number
STROBE items STROME-ID items
(Continued from previous page)
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic, clinical,
social) and information on exposures and potential confounders
b) Indicate the number of participants with missing data for each 
variable of interest
(c) Cohort study—summarise follow-up time (eg, average and total 
amount)
STROME-ID 14.1: give information by strain type if appropriate, with use of 
standardised nomenclature
Outcome data 15* Cohort study—report numbers of outcome events or summary measures 
over time
Case-control study—report numbers in each exposure category, 
or summary measures of exposure
Cross-sectional study—report numbers of outcome events or 
summary measures
··
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confi dence interval). Make clear
which confounders were adjusted for and why they were included
(b) Report category boundaries  when continuous variables were 
categorised
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period
STROME-ID 16.1: consider showing molecular relatedness of strain types by means 
of a dendrogram or phylogenetic tree
Other analyses 17 Report other analyses done (eg, analyses of subgroups and interactions, 
and sensitivity analyses)
··
Discussion
Key results 18 Summarise key results with reference to study objectives ··
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any 
potential bias
STROME-ID 19.1: consider alternative explanations for fi ndings when transmission 
chains are being investigated, and report the consistency between molecular and 
epidemiological evidence
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence
··
Generalisability 21 Discuss the generalisability (external validity) of the study results ··
Other information
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present article 
is based
··
Ethics 23 ·· STROME-ID 23.1: report any ethical considerations with specifi c implications for 
infectious-disease molecular epidemiology
STROBE=Strengthening the Reporting of Observational Studies in Epidemiology. STROME-ID=Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases. *Give such information separately 
for cases and controls in case-control studies, and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Table: The STROBE checklist and additional STROME-ID items
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timing of collection in relation to symptoms, use of 
antimicrobials at the time of collection, handling and 
storage of the sample before processing, timing of 
diff erent steps in sample processing, temperature, length 
of culture, and eff ectiveness of culture recovery can all 
aff ect the successful isolation and typing of an organism, 
and should be reported.30 Specimen workfl ow can also be 
an important variable, dependent on the study type.
For well established methods, authors should provide 
appropriate citations supporting the validity of the 
method, and if necessary explain how molecular 
measurements were interpreted.31 Standardisation of 
procedures across laboratories should be stated and 
referenced if done. The criteria used to identify strains 
according to molecular markers should be described in 
detail with reference to standard nomenclature, if 
available. Any variation from published interpretation 
protocols or deviation from standard nomenclature 
should be explicitly stated.
If the study describes specifi c methods or markers for 
specifi c epidemiological objectives or time-population 
frames, authors should report data for the validation of 
markers and the resolution capacity of these data within 
this context.44 Performance characteristics of molecular 
markers and analytical methods for molecular 
epidemiological studies include typability, reproducibility, 
discriminatory power, stability, and concordance with 
epidemiological evidence.31 Dependent on study design 
and typing method, portability of data between databases 
might be important.31 A description of reporting practice 
for assay type, detection limit, reliability of measurement, 
and calibration procedures has been documented 
elsewhere.30
Description of the molecular-typing methods used 
should be clearly linked to the epidemiological objectives, 
scope of the study, and description of molecular markers 
analysed. Investigators should ensure that the combined 
discriminatory power of the methods used is suffi  cient to 
achieve the objectives of the study. The discriminatory 
ability of the typing system used should therefore be 
reported whenever possible (appendix).
Cross-contamination is a particular diffi  culty for 
infectious-disease research, and usually results in false-
positive cases. For example, fi ndings from several studies 
of tuberculosis have shown cross-contamination rates of 
2–4%,45,46 and rates can be higher if laboratory standards 
are poor. Authors should therefore describe any methods 
used to minimise cross-contamination, such as those 
described by the Guidelines for Australian Mycobacterial 
Laboratories,47 and report cross-contamination rates if 
measured.
Setting
Clearly state the timeframe of the study; consider and 
appropriately reference the molecular clock of markers if 
known, and the natural history of the infection 
(STROME-ID 5.1). The timeframe of a study has 
particular importance in investigations of pathogen 
relatedness and transmission. Any epidemiological 
inferences made about transmission events on the basis 
of molecular diff erences between pathogens need to be 
consistent with the pathogen, the timeframe of the study, 
and the molecular clock of the marker used (appendix). 
The study timeframe should therefore be clearly stated, 
taking into account other factors such as spatial context, 
social networks, and background prevalences.
The term clustering is used to denote groups of 
individuals that are more similar to each other than to 
members of another group. When clustering refers to 
the grouping of pathogens by molecular markers, the 
proportion clustered tends to increase with time, 
reaching a plateau that depends on the molecular clock 
of the marker.48
For transmission studies, key characteristics of a 
pathogen’s natural history should also be considered 
with respect to the timeframe, and reported accordingly. 
These characteristics include serial intervals and 
infectious and incubation periods. For example, if two 
patients are infected with a similar strain, but have 
disease symptoms within less than the shortest possible 
serial interval for the infection, direct transmission could 
not have occurred.
Participants
State the source of participants and clinical specimens, 
and clearly describe sampling frame and strategy 
(STROME-ID 6.1). Selection of participants and samples 
is a potential source of bias for infectious-disease 
molecular epidemiology, as for many other epidemiol-
ogical studies. Infectious-disease clinical research 
frequently includes selection methods that need specifi c 
reporting considerations. These methods include case 
fi nding, contract tracing, surveillance programmes, and 
convenience sampling, which can aff ect representativeness 
of samples and generalisability of the results.
A key variable is whether all consecutive incident cases 
in an exposed population, or only a selected subset, are 
sampled. To increase the proportion of cases identifi ed, a 
study can include active case fi nding or contact tracing; 
investigators of a case-control study49 about infection 
with hepatitis A used sequence data to link cases in 
several US states to a single food source. In some 
instances, such case fi nding can aff ect the validity of 
assumptions about the independence of cases and 
increase the likelihood of identifi cation of related strains. 
Whether this eff ect of case fi nding aff ects valid inference 
from study fi ndings depends on the study question. 
STROME-ID 12.1 describes in more detail how statistical 
methods may be used to take account of this issue.
For studies using surveillance programmes and 
organisation networks for typing to obtain samples, 
authors should provide information about the 
representativeness of samples and generalisability of 
results, in addition to information about the underlying 
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population from which samples are obtained 
(STROME-ID 2.1). The European Centre for Disease 
Prevention and Control has proposed key design features 
for eff ective and consistent networks that collect 
representative isolates.13 These lend support to several 
STROME-ID components including agreement about a 
minimum dataset, a common typing approach, a suitable 
timeframe, rules about sample submission, and regular 
calibration of the structure and molecular diversity of the 
baseline population.13 Authors should also consider and 
comment on bias associated with reference strains and 
database collections, which are more likely than samples 
from the whole population to contain pathogenic, 
clinically relevant strains and opportunistic samples.50
Use of convenience sampling (eg, a sample defi ned by 
a geographical location or clinical service) can reduce the 
representativeness of samples and generalisability of a 
study, and tends to overestimate eff ects measured by 
clustering (STROME-ID 13.2).
Data source and measurement
Describe any methods used to detect multiple-strain 
infections and measure their eff ect on the study fi ndings 
(STROME-ID 8.1). Several distinct strains of a pathogen 
can simultaneously infect individual hosts, which can 
substantially complicate the design and analysis of 
fi ndings from molecular epidemiological studies.
Multiple-strain infections occur with a wide range of 
human pathogens (eg, viruses, bacteria, fungi, protozoa, 
and helminths) and the prevalence of detectable multiple-
strain infections is sometimes high (median 11·3%, 
mean 21·7% of infections), even with use of fairly 
insensitive detection methods.36 Multiple-strain infections 
of congenital cytomegalovirus were isolated from a single 
anatomical site and from diff erent sites in the same host.51 
For some pathogens (eg, RNA viruses such as dengue 
and HIV) in-host variability is a mandatory event driven 
by low proofreading fi delity of the viral RNA polymerase, 
which leads to the accumulation of variants known as 
quasispecies.52,53 This diff erentiation makes detection of 
multiple-strain infections more diffi  cult.
The probability of detection of multiple-strain 
infections, when present, depends on the design, 
execution, and analysis of the study. Factors described in 
STROME-ID 4.1–4.4, including sample collection (eg, 
number and type), sample transportation and storage, 
laboratory processing (eg, decontamination, culture, and 
subculture), selection of isolates for molecular typing, 
and the molecular-typing method used, all aff ect the 
likelihood of detection of multiple-strain infections and 
the ability of researchers to interpret fi ndings in the 
presence of this type of heterogeneity.
Molecular-typing methods that can identify more 
alleles at a single locus than are possible within a single 
strain (eg, mycobacterial interspersed repetitive unit-
variable number tandem repeat typing54) might be the 
most useful to identify the presence of multiple-strain 
infections. By contrast, typing methods that assess the 
presence or absence of specifi c markers (eg, spacer 
oligonucleotide typing55) can produce results that are 
diffi  cult to interpret in the presence of multiple-strain 
infections. Some computational methods to identify 
patterns that are consistent with multiple-strain infect-
ions have been suggested.56
When reporting results, authors should consider, and 
report if appropriate, to what extent multiple-strain 
infections could alter interpretations of their fi ndings.57 If 
multiple-strain infections have been detected, authors 
should state this fi nding and clearly describe how their 
analysis has accounted for such complex infections. In 
reports of studies for which multiple-strain infections 
might be present but have not been detected, authors 
should discuss how infection with several strains might 
aff ect the interpretation of their results.
Bias
Describe any eff orts made to address discovery or 
ascertainment bias (STROME-ID 9.1). Single nucleotide 
polymorphisms (SNPs) are widely used to identify 
sequence variation within pathogen populations.58 This 
method usually needs a set of wholly sequenced strains 
that constitute a panel of genetic variation (identifi ed by 
SNPs) across a pathogen’s genome, which is used to 
defi ne sequence variation in new strains.59 Use of a subset 
of sequences to defi ne the whole population with a set of 
SNPs can introduce bias, because subgroups are defi ned 
by the strains included. This issue has been called 
discovery or ascertainment bias, and can lead to so-called 
branch collapse that was fi rst used to describe the 
bamboo-like evolutionary trees sometimes resulting from 
the use of SNPs to explore evolution of M tuberculosis.60 
Pearson and colleagues61 subsequently reported methods 
to defi ne and control for ascertainment bias in modelling 
studies of Bacillus anthracis genomes. Authors should 
mention whether their results could be subject to this 
form of bias, and describe whether additional analyses 
have been done to take account of these eff ects.
Study size
Describe any unique restrictions placed on the study 
sample size (STROME-ID 10.1). Technological advances 
and the falling unit cost of molecular assays tend to 
increase the ability of researchers to process large numbers 
of samples.62 However, molecular epidemiological studies 
can still be associated with high laboratory costs and 
logistic troubles. This diffi  culty can place greater limits on 
the ability of researchers to obtain adequate sample sizes 
for molecular epidemiological studies than for other 
epidemiological studies.63 When the sample size is smaller 
than ideal, type 2 errors will be more common, such that 
the study fi ndings might be insuffi  cient to justify a 
conclusion. Authors should report when the power of the 
study has been limited by technical, fi nancial, or other 
such constraints.
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Statistical methods
State how the study took account of the non-independence 
of sample data, if appropriate (STROME-ID 12.1). Non-
independence of molecular data needs careful 
consideration in the reporting of infectious-disease 
molecular epidemiological studies. This diffi  culty can be 
caused by the fact that samples tend to be collected from 
predetermined groups of patients (eg, wards or hospitals) 
and that individuals within these groups are more likely 
to be similar to each other than to unrelated individuals. 
Furthermore, the very nature of infections—ie, 
transmission from one person to another—also 
introduces grouping of events in both time and space. 
For example, one of the main reasons to analyse 
surveillance data is to identify unusual clusters of events.
The statistical methods used should address the lack of 
independence between individuals. For some study 
fi ndings, the aggregation of individual data into larger 
units can be dealt with by directly accounting for the 
structure of the dataset during statistical analysis—eg, by 
introduction of random eff ects in a statistical regression 
model.
State how the study dealt with missing data 
(STROME-ID 12.2). Systematic diff erences between 
cases with and without missing molecular data can 
introduce bias (appendix). As such, we suggest that 
authors should avoid using the availability of data as an 
inclusion criterion. As for other studies, the level of 
completeness should always be declared and the 
implications of the level discussed. Authors should 
provide information about the type of missingness—ie, 
missing wholly at random, missing at random, or 
missing not at random. Statistical methods used to 
handle missing data should be stated and justifi ed.64 
Missing data can be a particular diffi  culty when molecular 
data are used to track and link transmissions, because 
parts of the transmission chain will be unidentifi able. 
For example, in analyses of data for M tuberculosis 
outbreaks, recent transmission is often inferred from the 
proportion of individuals with shared strains, but this 
outcome is underestimated when data are incomplete.22,64 
Further detailed descriptions about potential bias 
introduced by missing data are mentioned in the 
STROBE statement and supporting publications.21,26
Results
Participants
Report numbers of participants and samples at each stage 
of the study, including the number of samples obtained, 
the number typed, and the number yielding data 
(STROME-ID 13.1). In addition to STROBE 13,21,26 authors 
should consider specifi c factors that might contribute to 
missing data for molecular typing for pathogens 
(appendix), and report numbers of participants (and 
numbers of samples if diff erent) at each stage of sample 
processing, including at isolation, culture, and typing 
stages as appropriate.
If the study investigates groups of genetically 
indistinguishable pathogens (molecular clusters), state 
the sampling fraction, the distribution of cluster sizes, 
and the study population turnover, if known 
(STROME-ID 13.2). In studies of groups of genetically 
indistinguishable pathogens (molecular clusters), 
analyses can be subject to several biases. Reporting of the 
sampling fraction, the distribution of cluster sizes, and 
the study population turnover helps readers interpret the 
extent to which these biases exist in such cases.
The sampling fraction is the number of cases in the 
study as a proportion of all cases occurring in the 
population (including those not detected). Generally, 
increasing the sampling fraction tends to increase the 
proportion of samples that are clustered, with diminishing 
returns towards a plateau representing the true proportion 
clustering in a population.48,65 For M tuberculosis, the 
proportion of clustered M tuberculosis strains detected in a 
population provides a proxy measure of recent infections.66 
Methods used to estimate the proportion of clustered and 
unique cases can be biased if the sample does not include 
all the cases in the population.22,48 Reporting of the 
sampling fraction therefore allows assessment of the 
potential for bias in this estimate.67 If the population size is 
not known, the likelihood of clustering bias can be inferred 
from the distribution of cluster sizes, which also shows the 
presence of dominant strains in the population studied.44
Several methods are available to estimate the proportion 
of cases clustered.64 For example, the N method sums all 
cases reported in a cluster, and is often used in investigation 
of transmission chains. The N – 1 method assumes one 
case in each cluster is the index and adjusts the total 
accordingly. The method used should be stated clearly.
Population turnover will also aff ect detection of 
molecular clustering. For example, in a population with 
high immigration rates, more unique cases than would 
be expected will be detected if compared with a closed 
population. Selective emigration of infected or non-
infected people in the study population will also aff ect 
clustering measures.64 The turnover of the study 
population and the migration status of participants 
should therefore be reported if known.44
Another consideration for measures of molecular 
clustering is the establishment of latent infection by 
organisms such as M tuberculosis and some herpes viruses. 
Reactivation in individuals infected in large historical 
clusters could lead to the identifi cation of clustering for 
later cases with no immediately obvious epidemiological 
links, which could lead to misinterpretation.68
Descriptive data
Give information by strain type if appropriate, with use 
of standardised nomenclature (STROME-ID 14.1). The 
analysis and reporting by strain type of epidemiological 
information (demographic, clinical, and behavioural) can 
be informative in some studies. Statistical models might 
need stratifi cation by pathogen strains, and authors 
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should therefore report suffi  cient detail for readers to 
understand the appropriateness of decisions about 
model construction. For example, a study69 of meticillin-
resistant S aureus compared characteristics of patients 
infected with the USA100 strain with those of patients 
infected with the USA300 strain, and assessed the 
antibiotic resistance profi le of both strains. Whenever 
possible, standardised nomenclature, for example using 
publicly available multilocus sequence typing databases,1 
should be used to facilitate comparisons between studies.
Main results
Consider showing molecular relatedness of strain types 
by means of a dendrogram or phylogenetic tree 
(STROME-ID 16.1). Dendrograms or other graphical 
representational methods can be used to depict quant-
itative estimates of divergence within and between 
strains, typically done in reference to an unrelated control 
strain.70 If the typing methods used provide valid 
estimates for the genetic distance between strains, 
phylogenetic trees can be computed with use of 
appropriate algorithms and bootstrap analysis, and the 
results can be displayed as a tree indicating statistical CIs 
for the branch nodes.1,70
Discussion
Limitations
 
Consider alternative explanations for fi ndings when 
transmission chains are being investigated, and report 
the consistency between molecular and epidemiological 
evidence (STROME-ID 19.1). For any putative
transmission chain from person A to person B, several 
diff erent scenarios might reasonably account for two 
individuals being infected with identical or closely related 
pathogens.71 These scenarios include diff erent directions 
of transmission (A to B or B to A), intervening cases 
(A to C to B), and a common source (C to A and C to B). 
The direction of transmission, and whether intervening 
(possibly undiagnosed) cases have not occurred, can be 
particularly diffi  cult to establish. These diffi  culties have 
been well described when molecular-typing evidence has 
been used in legal settings.72,73 Such cases show that 
transmission is much easier to disprove than to prove 
beyond doubt. Furthermore, litigation cases show that 
molecular data are of little value without linked 
epidemiological data, which provide essential supportive 
evidence for any conclusions drawn.74 Epidemiological 
and molecular evidence therefore need to be considered 
together and checked for consistency.12
At a population level, the infection network can be far 
wider than the cases studied, with many unknown and 
unknowable transmissions occurring.3 Pathogens can be 
transmitted from the environment, animals, or other 
individuals, and through many diff erent transmission 
routes (eg, airborne, ingested, direct contact, sexual 
contact, vertical, and others). For these reasons, authors 
should consider reporting on the one hand whether 
distinct transmission chains might show evolutionary 
convergence, and on the other whether infections with 
several strains can occur simultaneously (appendix).
Other information
Ethics
Report any ethical considerations with specifi c implic-
ations for infectious-disease molecular epidemiology 
(STROME-ID 23.1). Bioethical principles, such as those set 
out by Beauchamp and Childress,75 should guide res-
earchers of all studies involving human participants, and 
studies should be reviewed by accredited research ethics 
committees or their equivalent. For studies in which direct 
transmission of infections is investigated, fully informed 
consent and confi dentiality are of paramount importance.76 
In extreme cases, studies can have legislative implications 
in countries where individuals have been prosecuted 
under criminal law for exposing others to infections such 
as HIV,71,77 hepatitis B virus,78 and herpes simplex virus.79 
The decision as to whether or not to return results to 
participants should also be presented and justifi ed by 
authors,80 taking into account the public health implications 
for people who have been in contact with those diagnosed 
with (possibly asymptomatic) infections. Authors should 
therefore report ethical approval.
Conclusions
The STROME-ID statement aims to support transparent 
reporting of research (rather than to guide research 
methods) and emphasises specifi c examples for which 
epidemiological research into infectious diseases can be 
subject to interpretation errors because of misleading 
reporting of molecular data. We have given particular 
emphasis to the interpretation of fi ndings and the 
transparent description of limitations in this context. 
This statement has been designed to be directly useful to 
authors and we expect it to be highly relevant to 
scientists, clinicians, public health specialists, journal 
staff , and grant reviewers with an interest in infectious 
diseases. Its longevity and eff ect will depend on wide 
dissemination and systematic use. To this end, we have 
developed the statement following the example of the 
widely applied STROBE collaboration.
We acknowledge several limitations in this statement. 
We have reached consensus through iterative revisions 
by contributors mostly from Europe and North America 
who were identifi ed through scientifi c networks. The 
state ment is intentionally written from an 
epidemiological perspective (rather than with a 
laboratory focus), and is probably aff ected by the 
composition of this group. In common with other 
similar statements, we have not done a formal 
systematic review for each item of the check list.21,30 
Reporting guidelines can improve the quality of 
published articles,81 but we recognise that authors are 
often limited by word count and that many high-quality 
studies are published in the form of short reports; 
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compliance with every item of this statement might not 
be possible. Many journals increasingly provide oppor-
tunities to publish additional material online, and such 
options should be used to ensure full reporting of high-
quality research without limiting publication.
Finally, we recognise that STROME-ID must form the 
basis for a work in progress, and we expect and welcome 
comments relating to structure, content, and use of this 
statement. In the near future, whole-genome 
sequencing and proteomics applications will provide 
additional typing resolution that is not feasible at 
present, and we expect the emergence of these and 
other technologies with new epidemiological 
applications that might necessitate future revisions. 
Likewise, the use of mol ecular data might be extended 
beyond purely observational studies and used in trials 
and interventions, which could warrant further 
reporting considerations. Nevertheless, we expect that 
many of the underlying principles, as described, will 
remain highly relevant.
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